These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 27395403)

  • 41. Long-term safety and tolerability of aripiprazole lauroxil in patients with schizophrenia.
    Nasrallah HA; Aquila R; Du Y; Stanford AD; Claxton A; Weiden PJ
    CNS Spectr; 2019 Aug; 24(4):395-403. PubMed ID: 30109845
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Inhibition of Recombinant Human Acetylcholinesterase Activity by Antipsychotics.
    Obara K; Fujii A; Arie C; Harada N; Yamaki F; Matsuo K; Yoshio T; Tanaka Y
    Pharmacology; 2019; 104(1-2):43-50. PubMed ID: 31067549
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Extrapyramidal side effects with atypical neuroleptics in bipolar disorder.
    Ghaemi SN; Hsu DJ; Rosenquist KJ; Pardo TB; Goodwin FK
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Mar; 30(2):209-13. PubMed ID: 16412546
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia.
    Findling RL; Robb A; Nyilas M; Forbes RA; Jin N; Ivanova S; Marcus R; McQuade RD; Iwamoto T; Carson WH
    Am J Psychiatry; 2008 Nov; 165(11):1432-41. PubMed ID: 18765484
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment challenges and safety considerations for antipsychotic use in children and adolescents with psychoses.
    McConville BJ; Sorter MT
    J Clin Psychiatry; 2004; 65 Suppl 6():20-9. PubMed ID: 15104523
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antipsychotic medication in adolescents suffering from schizophrenia: a meta-analysis of randomized controlled trials.
    Ardizzone I; Nardecchia F; Marconi A; Carratelli TI; Ferrara M
    Psychopharmacol Bull; 2010; 43(2):45-66. PubMed ID: 21052042
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Drug safety evaluation of aripiprazole in bipolar disorder.
    Cuomo A; Beccarini Crescenzi B; Goracci A; Bolognesi S; Giordano N; Rossi R; Facchi E; Neal SM; Fagiolini A
    Expert Opin Drug Saf; 2019 Jun; 18(6):455-463. PubMed ID: 31072228
    [No Abstract]   [Full Text] [Related]  

  • 48. Clinical relationship of extrapyramidal symptoms and tardive dyskinesia.
    Andrew HG
    Can J Psychiatry; 1994 Nov; 39(9 Suppl 2):S76-80. PubMed ID: 7874668
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Early extrapyramidal side-effects as risk factors for later tardive dyskinesia: a prospective study.
    Sachdev P
    Aust N Z J Psychiatry; 2004 Jun; 38(6):445-9. PubMed ID: 15209837
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Aripiprazole in pediatric psychosis and bipolar disorder: a clinical review.
    Doey T
    J Affect Disord; 2012; 138 Suppl():S15-21. PubMed ID: 22406333
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A meta-analysis of efficacy and safety of aripiprazole in adult and pediatric bipolar disorder in randomized controlled trials and observational studies.
    Meduri M; Gregoraci G; Baglivo V; Balestrieri M; Isola M; Brambilla P
    J Affect Disord; 2016 Feb; 191():187-208. PubMed ID: 26674213
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment predictors of extrapyramidal side effects in patients with tardive dyskinesia: results from Veterans Affairs Cooperative Study 394.
    Lohr JB; Caligiuri MP; Edson R; Lavori P; Adler LA; Rotrosen J; Hitzemann R
    J Clin Psychopharmacol; 2002 Apr; 22(2):196-200. PubMed ID: 11910266
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Weight-Change Trajectories of Pediatric Outpatients Treated with Risperidone or Aripiprazole in a Naturalistic Setting.
    Pozzi M; Pisano S; Marano G; Carnovale C; Bravaccio C; Rafaniello C; Capuano A; Rossi F; Rizzo R; Bernardini R; Nobile M; Molteni M; Clementi E; Biganzoli E; Radice S
    J Child Adolesc Psychopharmacol; 2019 Mar; 29(2):133-140. PubMed ID: 30452281
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evidence that early extrapyramidal symptoms predict later tardive dyskinesia: a prospective analysis of 10,000 patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) study.
    Tenback DE; van Harten PN; Slooff CJ; van Os J
    Am J Psychiatry; 2006 Aug; 163(8):1438-40. PubMed ID: 16877660
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antipsychotic drugs and extrapyramidal side effects in first episode psychosis: a systematic review of head-head comparisons.
    Haddad PM; Das A; Keyhani S; Chaudhry IB
    J Psychopharmacol; 2012 May; 26(5 Suppl):15-26. PubMed ID: 22057019
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Weight gain and other metabolic adverse effects associated with atypical antipsychotic treatment of children and adolescents: a systematic review and meta-analysis.
    Almandil NB; Liu Y; Murray ML; Besag FM; Aitchison KJ; Wong IC
    Paediatr Drugs; 2013 Apr; 15(2):139-50. PubMed ID: 23519708
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics.
    Miller CH; Mohr F; Umbricht D; Woerner M; Fleischhacker WW; Lieberman JA
    J Clin Psychiatry; 1998 Feb; 59(2):69-75. PubMed ID: 9501888
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Will the new antipsychotics bring hope of reducing the risk of developing extrapyramidal syndromes and tardive dyskinesia?
    Casey DE
    Int Clin Psychopharmacol; 1997 Feb; 12 Suppl 1():S19-27. PubMed ID: 9179640
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparative efficacy, tolerability, and acceptability of pharmacological interventions for the treatment of children, adolescents, and young adults with Tourette's syndrome: a systematic review and network meta-analysis.
    Farhat LC; Behling E; Landeros-Weisenberger A; Levine JLS; Macul Ferreira de Barros P; Wang Z; Bloch MH
    Lancet Child Adolesc Health; 2023 Feb; 7(2):112-126. PubMed ID: 36528030
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of the Expression Profile of Extrapyramidal Symptoms Due to Antipsychotics by Data Mining of Japanese Adverse Drug Event Report (JADER) Database.
    Kose E; Uno K; Hayashi H
    Yakugaku Zasshi; 2017; 137(1):111-120. PubMed ID: 28049887
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.